Cenra Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Cenra.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 59.5% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
China Chemical & Pharmaceutical's (TWSE:1701) Dividend Will Be Reduced To NT$0.50
Jul 12
Here's Why We Think China Chemical & Pharmaceutical (TPE:1701) Is Well Worth Watching
Apr 25We Think China Chemical & Pharmaceutical (TPE:1701) Can Stay On Top Of Its Debt
Apr 07The China Chemical & Pharmaceutical (TPE:1701) Share Price Is Up 34% And Shareholders Are Holding On
Mar 17China Chemical & Pharmaceutical Co., Ltd.'s (TPE:1701) Stock Has Shown A Decent Performance: Have Financials A Role To Play?
Feb 24Is China Chemical & Pharmaceutical Co., Ltd. (TPE:1701) A Good Fit For Your Dividend Portfolio?
Jan 27
Does China Chemical & Pharmaceutical (TPE:1701) Have A Healthy Balance Sheet?
Jan 06The China Chemical & Pharmaceutical (TPE:1701) Share Price Is Up 22% And Shareholders Are Holding On
Dec 16China Chemical & Pharmaceutical Co., Ltd. (TPE:1701) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Nov 26In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cenra has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | 8,871 | 355 | 317 | 636 | N/A |
| 3/31/2024 | 8,762 | 328 | 258 | 571 | N/A |
| 12/31/2023 | 8,575 | 322 | 340 | 602 | N/A |
| 9/30/2023 | 8,619 | 317 | 217 | 487 | N/A |
| 6/30/2023 | 8,599 | 387 | 301 | 585 | N/A |
| 3/31/2023 | 8,572 | 489 | 216 | 485 | N/A |
| 12/31/2022 | 8,457 | 478 | -96 | 167 | N/A |
| 9/30/2022 | 8,147 | 526 | -216 | 42 | N/A |
| 6/30/2022 | 7,981 | 528 | 50 | 277 | N/A |
| 3/31/2022 | 7,936 | 477 | 291 | 522 | N/A |
| 12/31/2021 | 7,949 | 518 | 488 | 696 | N/A |
| 9/30/2021 | 8,102 | 459 | 785 | 999 | N/A |
| 6/30/2021 | 8,211 | 448 | 596 | 833 | N/A |
| 3/31/2021 | 8,088 | 574 | 468 | 707 | N/A |
| 12/31/2020 | 8,181 | 557 | 625 | 897 | N/A |
| 9/30/2020 | 8,061 | 531 | 365 | 658 | N/A |
| 6/30/2020 | 8,006 | 512 | 425 | 738 | N/A |
| 3/31/2020 | 8,075 | 412 | 79 | 603 | N/A |
| 12/31/2019 | 7,970 | 385 | -165 | 328 | N/A |
| 9/30/2019 | 7,630 | 360 | -423 | 67 | N/A |
| 6/30/2019 | 7,669 | 368 | -403 | 38 | N/A |
| 3/31/2019 | 7,547 | 343 | -300 | -78 | N/A |
| 12/31/2018 | 7,580 | 370 | -64 | 153 | N/A |
| 9/30/2018 | 7,562 | 374 | 140 | 321 | N/A |
| 6/30/2018 | 7,083 | 372 | 188 | 354 | N/A |
| 3/31/2018 | 6,714 | 326 | N/A | 449 | N/A |
| 12/31/2017 | 6,245 | 311 | N/A | 462 | N/A |
| 9/30/2017 | 5,988 | 293 | N/A | 419 | N/A |
| 6/30/2017 | 5,848 | 257 | N/A | 397 | N/A |
| 3/31/2017 | 5,822 | 305 | N/A | 471 | N/A |
| 12/31/2016 | 5,781 | 313 | N/A | 194 | N/A |
| 9/30/2016 | 5,785 | 311 | N/A | 383 | N/A |
| 6/30/2016 | 5,771 | 362 | N/A | 447 | N/A |
| 3/31/2016 | 5,717 | 352 | N/A | 421 | N/A |
| 12/31/2015 | 5,628 | 354 | N/A | 555 | N/A |
| 9/30/2015 | 5,568 | 450 | N/A | 378 | N/A |
| 6/30/2015 | 5,471 | 395 | N/A | 254 | N/A |
| 3/31/2015 | 5,350 | 384 | N/A | 224 | N/A |
| 12/31/2014 | 5,297 | 348 | N/A | 330 | N/A |
| 9/30/2014 | 5,257 | 253 | N/A | 441 | N/A |
| 6/30/2014 | 5,274 | 260 | N/A | 641 | N/A |
| 3/31/2014 | 5,271 | 266 | N/A | 581 | N/A |
| 12/31/2013 | 5,174 | 240 | N/A | 405 | N/A |
| 9/30/2013 | 5,125 | 256 | N/A | 471 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 1701's forecast earnings growth is above the savings rate (1%).
Earnings vs Market: Insufficient data to determine if 1701's earnings are forecast to grow faster than the TW market
High Growth Earnings: Insufficient data to determine if 1701's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 1701's revenue is forecast to grow faster than the TW market.
High Growth Revenue: Insufficient data to determine if 1701's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1701's Return on Equity is forecast to be high in 3 years time